Ketamine Responders Had a Different Immune Signature Before Their First Dose
Patients who responded to ketamine looked different in a blood test before they were ever dosed. A National Institute of Mental Health team reported the finding in Molecular Psychiatry. It is the clearest step yet toward predicting who will respond.
Knowing who responds would change the economics of every chair in the building. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| The study | NIMH-led work in Molecular Psychiatry combining stem cell and clinical data |
| The clinical sample | 39 treatment-resistant patients and 25 healthy volunteers, one IV dose |
| The baseline signal | Eventual responders showed lower interleukin-15 before treatment |
| The shared pathway | 103 proteins moved by ketamine, 86 percent also moved by psychedelics |
| The two hubs | Interleukin-15 and monocyte chemoattractant protein-1 |
| The status | Exploratory. The authors call for larger independent replication |
What the Team Did
This was not a single experiment. The group combined several lines of evidence.
They ran proteomics on cerebrospinal fluid from healthy volunteers given intravenous ketamine.
They grew neurons from stem cells derived from patients with treatment-resistant depression and from healthy volunteers. Those cells were then treated with ketamine, with its metabolite hydroxynorketamine, with LSD or with psilocybin.
Alongside that, 39 patients with treatment-resistant depression and 25 healthy volunteers were dosed. Each received a single intravenous dose of ketamine at 0.5 mg/kg or placebo, with blood cytokines measured.
The senior author is Carlos Zarate at NIMH, whose group ran much of the original clinical work on ketamine for depression. The paper is published in Molecular Psychiatry.
The Finding That Matters for a Clinic
Responders and non-responders differed before treatment started.
Patients who went on to respond showed lower interleukin-15 activity at baseline, alongside elevated B-cell signaling. After ketamine, both patterns reversed.
Two ratios also tracked with outcome. A higher ratio of monocyte chemoattractant protein-1 to interleukin-7 predicted worse response. A higher ratio of interleukin-4 to interferon gamma predicted better response.
Those are measurements from blood. That is the part worth sitting with.
Magnetoencephalography was run too, on 30 patients and 25 healthy volunteers, which is how the brain signal was tied to the blood signal.
Why Prediction Would Change the Business
Right now a clinic treats and waits. The infusion series runs, the scores come back, and only then does anybody know whether it worked.
A validated pre-treatment marker would change the conversation at intake. It would also change the conversation with payers, who fund treatments that can be targeted more readily than treatments that cannot.
It would help the patients who do not respond most of all. Those patients currently spend weeks and thousands of dollars finding out.
Clinics that already track outcomes systematically will be positioned to use a marker like this first, which is part of why sending scores back to referrers keeps paying off.
There is a second commercial angle. A clinic that can say which patients are most likely to benefit becomes a better referral partner, not just a better treater.
Referring psychiatrists send patients where the odds look good. A marker would make that judgment shared rather than guessed.
Ketamine and Psychedelics Converged
The second finding is about mechanism rather than prediction.
Ketamine altered 103 proteins in this work. Psychedelics moved 86 percent of the same set, despite acting on entirely different receptors.
Interleukin-15 and monocyte chemoattractant protein-1 emerged as the regulatory hubs where those paths met.
If rapid antidepressant response runs through a shared immune pathway, a clinic offering ketamine today is already working in the biology that approved psychedelics would use.
That convergence also matters for anyone planning a service line. Infrastructure built around one mechanism may transfer more readily than the receptor differences suggest.
What This Does Not Yet Support
The authors are direct that the work is exploratory, and the numbers explain why.
The transcriptomic arm included 16 patients and 11 healthy volunteers. The cytokine arm was larger at 39 and 25. These are mechanistic sample sizes, not diagnostic ones.
No test exists. Nothing here can be ordered for a patient, and no clinic should imply otherwise.
Replication in larger independent samples is the next step, and the authors say so.
One timing note. The paper went online in late July, so this is a fresh writeup of work that has been available for a couple of months.
Where It Fits With the Rest
This is the third angle on the same question we have covered this year.
Two imaging studies pointed at the day after the infusion as the moment that matters. A separate trial found ketamine raised morning cortisol in a pattern that tracked with outcome.
Each one is a different instrument pointed at the same target. Knowing who responds, and when, is the most valuable open question in this field.
How that gets measured is itself contested, as we found when looking at which questionnaire a clinic chooses.
Nothing to Do Yet, Plenty to Watch
A well resourced federal lab found an immune signature that separated responders from non-responders before anyone was treated.
It is early, it is small, and it needs replicating. It is also the kind of finding that eventually turns a treatment into a targeted one.
Clinics do not need to do anything with this yet. They do need to know it is coming, because the first operators with a validated marker will have a real advantage.
Patients looking for supervised care can start with our directory of verified ketamine clinics.
This article is for informational purposes and is not medical advice. No clinical test based on these findings is currently available.
